import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "how-to-use-semax-research-protocol-guide",
  title: "How to Use Semax: Research Protocol Guide",
  description:
    "A researcher's reference for Semax (ACTH 4-7 analog) — mechanism of action, reconstitution, intranasal administration protocols, dosing ranges from published studies, and storage requirements.",
  category: "Research Protocols",
  readMinutes: 9,
  publishedAt: "2026-06-20",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Semax is a synthetic heptapeptide analog of the ACTH 4-7 fragment, developed in Russia in the 1980s at the Institute of Molecular Genetics. Unlike full-length ACTH, Semax does not carry adrenocortical activity — it has been studied specifically for its effects on the central nervous system, particularly BDNF upregulation, neuroprotection, and cognitive modulation. It remains one of the most extensively investigated nootropic peptides with a substantial published record in both animal and early human studies.",
    },
    {
      type: "heading",
      text: "What Is Semax?",
    },
    {
      type: "paragraph",
      text: "The full sequence of Semax is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It is a modified fragment of corticotropin (ACTH), extended at the C-terminal with Pro-Gly-Pro to resist rapid enzymatic degradation in biological systems. This modification substantially extends the half-life compared to the native ACTH 4-7 tetrapeptide.",
    },
    {
      type: "paragraph",
      text: "Semax was approved in Russia as a nootropic and neuroprotective agent and has been used in clinical settings there for ischemic stroke, optic nerve atrophy, and attention-related disorders. Outside Russia, it is studied exclusively as a research compound. It is not approved by the FDA for any therapeutic use.",
    },
    {
      type: "heading",
      text: "Proposed Mechanisms of Action",
    },
    {
      type: "subheading",
      text: "BDNF and Neurotrophin Upregulation",
    },
    {
      type: "paragraph",
      text: "The most consistently replicated finding in Semax research is its ability to upregulate brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in hippocampal and frontal cortex tissue. BDNF is a critical mediator of synaptic plasticity, neuronal survival, and long-term potentiation — the cellular mechanism underlying learning and memory consolidation. Semax-mediated BDNF increases have been documented in rodent models across multiple research groups, typically peaking at 24–48 hours after administration.",
    },
    {
      type: "subheading",
      text: "Dopaminergic and Serotonergic Modulation",
    },
    {
      type: "paragraph",
      text: "Studies using microdialysis in rat models have shown Semax modulates dopamine and serotonin turnover in prefrontal cortex regions. This may account for the attention-enhancing effects reported in human clinical studies: Semax administration improved performance on sustained attention tasks in a placebo-controlled trial involving healthy volunteers. The neurochemical basis appears to involve dopamine D1/D4 receptor signaling rather than direct receptor agonism.",
    },
    {
      type: "subheading",
      text: "Neuroprotection Under Ischemic Conditions",
    },
    {
      type: "paragraph",
      text: "Russian clinical trials have assessed Semax in acute ischemic stroke patients, finding reductions in neurological deficit scores compared to control groups. In animal models, Semax reduces infarct volume when administered shortly after ischemic insult — effects attributed to modulation of HIF-1α expression, reduction of reactive oxygen species in neural tissue, and stabilization of mitochondrial membrane potential. These neuroprotective findings are among the most clinically relevant aspects of the Semax research literature.",
    },
    {
      type: "heading",
      text: "Reconstitution Protocol",
    },
    {
      type: "paragraph",
      text: "Semax is supplied as a lyophilized powder. It is water-soluble and stable in aqueous solution relative to many other neuropeptides, but reconstitution technique still matters for data reproducibility.",
    },
    {
      type: "list",
      items: [
        "Allow the vial to equilibrate to room temperature (approximately 15–20 minutes) before opening to prevent condensation entry",
        "Use bacteriostatic water (0.9% benzyl alcohol) as the diluent for multi-dose vials; sterile water for single-dose use",
        "Inject diluent slowly along the inner vial wall — do not inject directly onto the lyophilized cake, which can cause aggregation",
        "Gently swirl to dissolve; do not vortex or shake vigorously",
        "Standard concentration for intranasal research protocols: 300–750 mcg/mL",
        "For reference, a common 30 mg vial reconstituted with 3 mL produces 10 mg/mL (10,000 mcg/mL); dilute further as needed for intranasal dosing volumes",
      ],
    },
    {
      type: "heading",
      text: "Administration Routes in Research",
    },
    {
      type: "subheading",
      text: "Intranasal Administration",
    },
    {
      type: "paragraph",
      text: "Intranasal delivery is the primary administration route in Semax research — and for this peptide specifically, it has strong biological rationale. The nasal mucosa contains the olfactory nerve, which provides a direct axonal pathway to the olfactory bulb and, from there, to hippocampal and limbic structures. This nose-to-brain route allows neuropeptides to reach CNS targets while largely bypassing hepatic first-pass metabolism and the blood-brain barrier.",
    },
    {
      type: "paragraph",
      text: "Standard intranasal protocol in research models involves administration via micropipette or nasal atomizer device, with subjects in supine position. Volume per nostril is typically kept to 100–150 µL per dose to maximize absorption at the olfactory epithelium and minimize posterior drainage into the nasopharynx.",
    },
    {
      type: "subheading",
      text: "Subcutaneous and Intraperitoneal Routes",
    },
    {
      type: "paragraph",
      text: "In rodent research, Semax has been administered subcutaneously (SC) and intraperitoneally (IP) to bypass nasal delivery challenges in animal models. IP administration in particular provides rapid and reproducible systemic exposure and is commonly used when intranasal delivery is impractical for the study design. Bioavailability via IP route is generally higher than SC due to the peritoneal vasculature.",
    },
    {
      type: "heading",
      text: "Dosing Ranges in Published Research",
    },
    {
      type: "table",
      headers: ["Study Type", "Route", "Dose Range", "Frequency", "Duration"],
      rows: [
        ["Cognitive enhancement (human)", "Intranasal", "200–600 mcg/day", "1–2×/day", "7–30 days"],
        ["Ischemic neuroprotection (human)", "Intranasal", "1,000–3,000 mcg/day", "2–3×/day", "10–20 days"],
        ["BDNF upregulation (rodent)", "SC/IP", "50–250 mcg/kg", "1×/day", "7–14 days"],
        ["Attention/learning (rodent)", "IP", "100–500 mcg/kg", "30–60 min pre-test", "Acute or 5–14 days"],
      ],
    },
    {
      type: "paragraph",
      text: "Note: These ranges are drawn from published preclinical and early clinical literature. They are provided as a reference for study design, not as dosing recommendations. Researchers should review source publications and design protocols appropriate to their specific model system.",
    },
    {
      type: "heading",
      text: "Storage and Stability",
    },
    {
      type: "list",
      items: [
        "Lyophilized Semax: stable for 12–24 months at -20°C in sealed vials; 3–6 months at 2–8°C",
        "Reconstituted solution: refrigerate immediately at 2–8°C; use within 3–4 weeks",
        "Do not freeze reconstituted solution — ice crystal formation can disrupt peptide integrity",
        "Store in amber or opaque vials; Met residue is mildly light-sensitive",
        "Bring to room temperature before each use to prevent condensation on vial interior",
        "Label with compound name, lot number, reconstitution date, and concentration",
      ],
    },
    {
      type: "heading",
      text: "Experimental Design Considerations",
    },
    {
      type: "paragraph",
      text: "Semax research benefits from several design-level considerations that improve data quality and reproducibility.",
    },
    {
      type: "subheading",
      text: "BDNF Measurement Timing",
    },
    {
      type: "paragraph",
      text: "BDNF mRNA and protein levels peak at different post-administration intervals. mRNA increases appear within 3–6 hours; protein-level changes are typically measured at 12–48 hours. If BDNF is the primary endpoint, measurement timing should be specified in the protocol and consistent across subjects.",
    },
    {
      type: "subheading",
      text: "Behavioral Testing Windows",
    },
    {
      type: "paragraph",
      text: "Cognitive and behavioral endpoints (Morris water maze, fear conditioning, elevated plus maze for anxiety models) should be conducted during the expected peak activity window. For cognitive tasks, testing 30–60 minutes after intranasal or IP administration aligns with the reported peak CNS activity window in rodent models.",
    },
    {
      type: "subheading",
      text: "Vehicle Controls",
    },
    {
      type: "paragraph",
      text: "Bacteriostatic water (the standard diluent) should be used as the vehicle control rather than plain sterile water when using bacteriostatic water for reconstitution. Benzyl alcohol, even at the low concentrations in bacteriostatic water, has mild CNS effects in rodent models and should be accounted for in behavioral paradigms.",
    },
    {
      type: "heading",
      text: "Regulatory and Compliance Notes",
    },
    {
      type: "callout",
      text: "Semax is not approved for therapeutic use outside Russia and a small number of CIS countries. In the United States and European Union, it is classified as a research compound. All research involving Semax should comply with applicable institutional protocols (IACUC for animal studies), regulatory frameworks, and proper controlled substance guidelines where applicable. This article is for research reference only.",
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Semax is an ACTH 4-7 analog with a substantial preclinical record in BDNF upregulation, neuroprotection, and cognitive modulation. Intranasal delivery is the primary research route, supported by the nose-to-brain pathway. Reconstitution in bacteriostatic water at appropriate concentrations, proper refrigeration post-reconstitution, and careful experimental timing relative to BDNF peak windows are the key protocol variables for reproducible results.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use. All experiments involving research peptides should be conducted under applicable institutional oversight.",
    },
  ],
};
